» Articles » PMID: 33218044

Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Nov 21
PMID 33218044
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter, playing a central role in the regulation of cortical excitability and the maintenance of the excitatory/inhibitory (E/I) balance. Several lines of evidence point to a remodeling of the cerebral GABAergic system in Alzheimer's disease (AD), with past studies demonstrating alterations in GABA receptor and transporter expression, GABA synthesizing enzyme activity and focal GABA concentrations in post-mortem tissue. AD is a chronic neurodegenerative disorder with a poorly understood etiology and the temporal cortex is one of the earliest regions in the brain to be affected by AD neurodegeneration. Utilizing NanoString nCounter analysis, we demonstrate here the transcriptional downregulation of several GABA signaling components in the post-mortem human middle temporal gyrus (MTG) in AD, including the GABA receptor α, α, α, α, β, β, β, δ, γ, γ, and θ subunits and the GABA receptor 2 (GABAR2) subunit. In addition to this, we note the transcriptional upregulation of the betaine-GABA transporter (BGT1) and GABA transporter 2 (GAT2), and the downregulation of the 67 kDa isoform of glutamate decarboxylase (GAD), the primary GABA synthesizing enzyme. The functional consequences of these changes require further investigation, but such alterations may underlie disruptions to the E/I balance that are believed to contribute to cognitive decline in AD.

Citing Articles

The effect of probiotics on select cognitive domains in mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis.

Tripathi S, Kaushik M, Dwivedi R, Tiwari P, Tripathi M, Dada R J Alzheimers Dis Rep. 2025; 8(1):1422-1433.

PMID: 40034358 PMC: 11863739. DOI: 10.1177/25424823241289039.


Identification of early Alzheimer's disease subclass and signature genes based on PANoptosis genes.

Wang W, Lu J, Pan N, Zhang H, Dai J, Li J Front Immunol. 2024; 15:1462003.

PMID: 39650656 PMC: 11621049. DOI: 10.3389/fimmu.2024.1462003.


Exosomal mRNA Signatures as Predictive Biomarkers for Risk and Age of Onset in Alzheimer's Disease.

Bolivar D, Mosquera-Heredia M, Vidal O, Barcelo E, Allegri R, Morales L Int J Mol Sci. 2024; 25(22).

PMID: 39596356 PMC: 11594294. DOI: 10.3390/ijms252212293.


Brain-targeting liposome-based gene delivery exacerbates soluble amyloid-β accumulation in mice.

Wang N, Parsons T, Ren Y, Pan Y, Kurti A, Starling S Heliyon. 2024; 10(20):e39607.

PMID: 39506961 PMC: 11538761. DOI: 10.1016/j.heliyon.2024.e39607.


Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?.

Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J Front Pharmacol. 2024; 15:1459655.

PMID: 39355779 PMC: 11442227. DOI: 10.3389/fphar.2024.1459655.


References
1.
Pearson R, Esiri M, Hiorns R, Wilcock G, Powell T . Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci U S A. 1985; 82(13):4531-4. PMC: 391136. DOI: 10.1073/pnas.82.13.4531. View

2.
Reinikainen K, Paljarvi L, Huuskonen M, Soininen H, Laakso M, Riekkinen P . A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci. 1988; 84(1):101-16. DOI: 10.1016/0022-510x(88)90179-7. View

3.
Howell O, Atack J, Dewar D, McKernan R, Sur C . Density and pharmacology of alpha5 subunit-containing GABA(A) receptors are preserved in hippocampus of Alzheimer's disease patients. Neuroscience. 2000; 98(4):669-75. DOI: 10.1016/s0306-4522(00)00163-9. View

4.
Iwakiri M, Mizukami K, Ikonomovic M, Ishikawa M, Abrahamson E, DeKosky S . An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology. 2008; 29(3):263-9. PMC: 3078755. DOI: 10.1111/j.1440-1789.2008.00978.x. View

5.
Tian N, Petersen C, Kash S, Baekkeskov S, Copenhagen D, Nicoll R . The role of the synthetic enzyme GAD65 in the control of neuronal gamma-aminobutyric acid release. Proc Natl Acad Sci U S A. 1999; 96(22):12911-6. PMC: 23160. DOI: 10.1073/pnas.96.22.12911. View